Clinical significance of the TNF-α receptors, TNFRSF2 and TNFRSF9, on cell migration molecules Fascin-1 and Versican in acute leukemia
Clinical significance of the TNF-α receptors, TNFRSF2 and TNFRSF9, on cell migration molecules Fascin-1 and Versican in acute leukemia
复制标题
DOI：
10.1016/j.cyto.2018.05.025
复制
发表时间：
2018-11-01
期刊：
影响因子：
3.8
通讯作者：
Al-Gayyar, Mohammed M. H.
中科院分区：
文献类型：
--
作者：
El Kramani, Nabila;Elsherbiny, Nehal M.;Al-Gayyar, Mohammed M. H.
在人类恶性血液病中，一些TNF受体家族成员上调，并能够引起有利于肿瘤进展的反应。此外，细胞迁移分子Fascin-1和Versican参与癌细胞的增殖、迁移和侵袭。它们与许多人类癌症有关。因此，我们进行了这项研究，以评估急性白血病患者的肿瘤坏死因子受体超家族2（TNFRSF 2），TNFRSF 9，Fascin-1和Versican的血浆和白细胞浓度，以及这些值与临床特征和治疗结果的相关性。因此，纳入了48例急性髓性白血病（AML）患者、32例急性淋巴细胞白血病（ALL）患者和15例对照受试者。采用酶联免疫吸附法测定所有受试者血浆和白细胞中的TNFRSF 2、TNFRSF 9、Fascin-1和Versican。我们发现，与对照组相比，ALL和AML患者血浆TNFRSF 9水平显著升高。此外，未能达到完全缓解的AML患者显示白细胞TNFRSF 9水平显著升高。与对照组和AML患者相比，ALL患者的血浆和白细胞中TNFRSF 2显著升高。Fascin-1在AML中显著增加，但在ALL中不显著。与对照和ALL受试者相比，AML中Versican的血浆和白细胞水平显著增加。血浆Versican与AML患者对诱导化疗的不良反应相关。总之，TNFRSF 2和TNFRSF 9可作为ALL患者预后的可能生物标志物，TNFRSF 9可作为AML的潜在靶点。Versican可用作AML的诊断生物标志物和化疗反应的预测因子。此外，血浆Fascin-1是AML的潜在生物标志物。
In human hematologic malignancies, some of the TNF receptor family members are up-regulated and have the ability to evoke reactions favoring tumor progression. Moreover, cell migration molecules, Fascin-1 and Versican are involved in proliferation, migration and invasion of cancer cells. They are linked to many human cancers. Therefore, we conducted this study to evaluate both the plasma and leukocytes concentrations of tumor necrosis factor receptor super family 2 (TNFRSF2), TNFRSF9, Fascin-1 and Versican in patients with acute leukemia, as well as to correlate these values with clinical features and treatment outcome. Therefore, forty-eight patients with acute myeloid leukemia (AML), thirty-two patients with acute lymphoblastic leukemia (ALL) and fifteen control subjects were included. TNFRSF2, TNFRSF9, Fascin-1 and Versican were measured in plasma and leukocytes of all subjects by enzyme-linked immunosorbent assay. We found that plasma TNFRSF9 was highly elevated in ALL and AML as compared with the control group. In addition, AML patients who failed to achieve complete remission showed a significant increase in leukocytes TNFRSF9 level. TNFRSF2 is significantly increased in plasma and leukocytes of ALL patients when compared with the control group and AML patients. Fascin-1 significantly increased in AML, but not in ALL cases. Plasma and leukocytes levels of Versican significantly increased in AML compared to both control and ALL subjects. Plasma Versican correlated with poor response to induction of chemotherapy in AML cases. In conclusion, TNFRSF2 and TNFRSF9 could act as a possible prognostic biomarkers for the outcomes of ALL patients and TNFRSF9 could be a potential target in AML. Versican may be used as a diagnostic biomarker and as a predictor of the response to chemotherapy in AML. In addition, plasma Fascin-1 is a potential biomarker for AML.